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Abstract
Background: The coronavirus (COVID-19) pandemic has highlighted that individuals with behavioural risk factors
commonly associated with non-communicable diseases (NCDs), such as smoking, harmful alcohol use, obesity, and
physical inactivity, are more likely to experience severe symptoms from COVID-19. These risk factors have been
shown to increase the risk of NCDs, but less is known about their broader influence on communicable diseases.
Taking a wide focus on a range of common communicable diseases, this review aimed to synthesise research
examining the impact of behavioural risk factors commonly associated with NCDs on risks of contracting, or having
more severe outcomes from, communicable diseases.
Methods: Literature searches identified systematic reviews and meta-analyses that examined the association
between behavioural risk factors (alcohol, smoking, illicit drug use, physical inactivity, obesity and poor diet) and the
contraction/severity of common communicable diseases, including infection or associated pathogens. An a priori,
prospectively registered protocol was followed (PROSPERO; registration number CRD42020223890).
Results: Fifty-three systematic reviews were included, of which 36 were also meta-analyses. Reviews focused on:
tuberculosis, human immunodeficiency virus, hepatitis C virus, hepatitis B virus, invasive bacterial diseases, pneumonia,
influenza, and COVID-19. Twenty-one reviews examined the association between behavioural risk factors and
communicable disease contraction and 35 examined their association with communicable disease outcomes (three
examined their association with both contraction and outcomes). Fifty out of 53 reviews (94%) concluded that at least
one of the behavioural risk factors studied increased the risk of contracting or experiencing worse health outcomes
from a communicable disease. Across all reviews, effect sizes, where calculated, ranged from 0.83 to 8.22.
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Conclusions: Behavioural risk factors play a significant role in the risk of contracting and experiencing more severe
outcomes from communicable diseases. Prevention of communicable diseases is likely to be most successful if it
involves the prevention of behavioural risk factors commonly associated with NCDs. These findings are important for
understanding risks associated with communicable disease, and timely, given the COVID-19 pandemic and the need
for improvements in future pandemic preparedness. Addressing behavioural risk factors should be an important part of
work to build resilience against any emerging and future epidemics and pandemics.
Keywords: Infectious disease, COVID-19, Risk factors, Obesity, Smoking, Drug use, Alcohol, Prevention, Pandemic, Resilience
Background
The recent coronavirus (COVID-19) pandemic has
highlighted that individuals with potentially modifiable
behavioural risk factors that are commonly associated
with non-communicable diseases (NCDs), such as smok-
ing, harmful alcohol use, obesity and physical inactivity,
are more likely to experience severe symptoms from
COVID-19 infection [1], resulting in greater risk of hos-
pitalisation [2]. With these behavioural risk factors often
having higher prevalence in the poorest communities,
COVID-19 has disproportionately impacted those
already suffering the greatest risks of ill health, thereby
widening health and social inequalities [3]. Indeed, due
to its associations with existing health and social risk
factors, COVID-19 has been referred to as a syndemic;
one in which existing health and social challenges
increase an individual’s susceptibility to disease [4].
However, whilst addressing behavioural risk factors is
routinely considered in the prevention of NCDs, their
role in the contraction of communicable disease, and
severity of symptoms in those who are infected, has had
a lower public health prominence.
Many modifiable behavioural risk factors are highly
prevalent among adults and adolescents in both higher
(HICs) and lower and middle income countries (LMICs)
[5, 6], with levels increasing in many LMICs (e.g. obesity,
alcohol) [7, 8]. As a result, NCDs, such as cancer,
respiratory disease and cardiovascular disease are the
highest cause of mortality and morbidity in HICs and
account for a rapidly increasing proportion of both in
LMICs [9]. Across countries globally, the burden of
NCDs has been found to correlate with levels of
COVID-19 cases and deaths [10].
With both international commerce and tourism
connecting populations globally, it is highly likely
that COVID-19 is only one in a series of existing
and emerging infectious diseases likely to impact, to
different extents, health and well-being on a global
scale [11]. Although the exact nature or source of
any future epidemic or pandemic threat is specula-
tive, behavioural risk factors have also been found to
increase the risk of infection and subsequent poorer
outcomes across a range of other communicable
diseases [12–14]. Understanding which factors may
increase or reduce risk of contraction and severity of
disease can provide important intelligence, both in
increasing a population’s resilience to infectious
disease, and in identifying which communities and
individuals may be most at risk from the spread of
different types of disease. Although previous research
has explored links between behavioural risk factors
and individual communicable diseases, few studies
have synthesised information across a wider range of
communicable diseases and their relationships with
behavioural risks. Indeed, such relationships may
elucidate how future pandemics threats will exploit
behavioural risk factors.
Intending to explore whether communicable dis-
eases and NCDs share a common set of behavioural
risk factors, the aim of this review was to provide a
synthesis of existing research examining the impact
of behavioural risk factors commonly associated with
NCDs on the risk of people (adults or children)
contracting, or experiencing more severe outcomes
from, common communicable diseases. With the
breadth of communicable diseases requiring limita-
tion, the focus of this review was on diseases com-
mon to high income countries. With an intentionally
wide focus on a range of communicable diseases, the
review focused specifically on systematic reviews and
meta-analyses, clarifying existing knowledge and
highlighting gaps in evidence to inform priority areas
for future research.
Methods
This review was carried out in adherence to the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines. An a priori
protocol was followed and prospectively registered at
the National Institute for Health Research inter-
national prospective register of systematic reviews
(PROSPERO) (registration number CRD42020223890).
The focus of this review was limited to behavioural
risk factors and communicable diseases common in
HICs, regardless of the geographical location of the
review. Those more specific to LMICs or certain re-
gions of the world (e.g. tropical diseases) were consid-
ered best examined in a separate study.
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Search strategy
A systematic search was performed across multiple data-
bases through ProQuest covering the 10-year period
28th October 2010 to 28th October 2020. Preliminary
scans of the literature reviews and discussion between
members of the research team were used to aid selection
of common behavioural risk factors and communicable
diseases. Thus, alcohol use, smoking, physical inactivity,
obesity, illicit drug use and poor diet were chosen as be-
havioural risk factors, covering some of the most com-
mon behavioural contributors to NCDs [15]. The same
process identified: Tuberculosis (TB), acquired immune
deficiency syndrome (AIDS), human immunodeficiency
virus (HIV), viral hepatitis, COVID-19, severe acute
respiratory syndrome (SARS), middle-east respiratory
syndrome (MERS), pneumonia, influenza, and meningi-
tis as communicable diseases (including infections and
pathogens) feasible for review. These communicable
diseases were broadly consistent with some of the most
prevalent disease/infection categories reported in the
global burden of disease study for HICs (excluding those
categories predominantly affecting specific groups (e.g.
maternal, neonatal) or where a component may be asso-
ciated with non-infectious causes (e.g. diarrheal) [9]) and
with previous outbreaks or epidemics involving HICs
[16]. In addition, it was intended to include diseases that
arose from both bacterial and viral pathogens, with a
range of transmission types, e.g. airborne, droplet, fo-
mite, blood-borne and contact. Combinations of search
terms were developed based on these key risk factors
and diseases. Search results were restricted to English
language and peer reviewed systematic reviews and
meta-analyses. Whilst this strategy restricted literature
to that which qualified for inclusion in systematic
reviews, it allowed for the inclusion of multiple behav-
ioural risk factors and communicable diseases at the
same time. The search was restricted to a 10-year period,
allowing coverage of a broad range of behavioural risk
factors and communicable diseases, yet limiting the lit-
erature to a manageable volume. The full search strategy
is available in Supplementary file 1. Searches also in-
cluded poor housing conditions as a risk factor given the
impact of housing conditions on respiratory disease [17],
but this study focuses specifically on behavioural risk
factors.
Study selection and eligibility criteria
To identify eligible studies, the titles and abstracts of
studies retrieved were screened by two reviewers, with a
sample of 15% screened independently by both reviewers
and achieving 98.5% agreement (SH, NJ). Discrepancies
were resolved between reviewers. For full text screening,
ten reviews (7%) were initially screened by three re-
viewers (SH, NJ, SW), with results later discussed and
discrepancies resolved. Following this, the full text
screening was divided across reviewers and any reviews
that were not a clear exclude/include (20%) were dis-
cussed and agreed between reviewers. This meant that,
across all reviews screened by full text, 27% were dis-
cussed and agreed by more than one reviewer. Where
full texts could not be accessed, authors were contacted
to request the full text.
Systematic reviews and meta-analyses of observational
studies (including cohort and case-control studies) that
examined the association between an identified behav-
ioural risk factor and the contraction or outcomes of an
identified communicable disease (including infection or
related pathogens) were included in the review. Since
there are no single definitions of the selected risk factors
across the literature, all reviews that focused on an iden-
tified risk factor were included regardless of the defin-
ition used in the review (definitions are provided in
Tables 1 and 2 and in the results section). An aim of the
review was to explore risks associated with illicit drug
use in general. However, it was recognised that injection
drug use can be a mechanism of transmission for some
pathogens relating to included communicable diseases
(e.g. HIV, HCV). Studies that focused specifically on in-
jection drug use were therefore included alongside those
focusing on drug use more generally. Studies were
excluded if they: were not a systematic review or meta-
analysis; did not examine the association between an
selected behavioural risk factor and the contraction or
outcomes of an selected communicable disease; included
only selected specialist sub-populations (e.g. sex workers,
prisoners), or included sub-populations relating to a risk
factor (e.g. people who inject drugs) without a general
population comparison; or included behavioural risk fac-
tors or communicable diseases not relevant to HICs (see
above). No restrictions were made for the age of partici-
pants included. A flow chart demonstrating the selection
process is presented in Fig. 1.
Data extraction and synthesis
Data were extracted by three reviewers (SH, NJ, SW)
into a standardised, pre-piloted form. Each extraction
was duplicated across reviewers and discrepancies re-
solved through discussion. Information extracted from
the studies included: title, authors, abstract, behavioural
risk factor(s) studied, communicable disease(s) studied
(including infection or related pathogens), research
question, geographical restrictions, population character-
istics, number of reviews included in the systematic
review or meta-analysis, main findings (including odds
ratios (OR), relative risks (RR) or rate ratios where
available), proposed mechanisms of association and
conclusions related to identified behavioural risk fac-
tor(s) and communicable disease(s). Where information
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Table 1 Results and main conclusions relating to identified risk factors from included studies: risk of contraction
Disease
contracted
Ref Definition of risk factor Meta-analysis findings No. of
studiesa
Conclusionb
Comparison group Effect size (95% CI) Effect
direction
Alcohol as a risk factor
TB [18] Any alcohol use or higher
amounts
No alcohol or lower
amounts
OR 1.90 (1.63–2.23) 44 ↑
[19] Alcohol consumption N/A Unclear –




[21] Any alcohol use or higher
amounts
No alcohol or lower
amounts
RR 1.83 (1.30–2.57) 14 ↑
[22] AUD No AUD RR 8.22 (4.85–13.95) 2 ↑
IBD (IPD) [23] Alcohol consumption N/A 6 ↑
Illicit drug use as a risk factor
TB [19] Drug abuse – Unclear –
[24] Injection drug use – Unclear ↑
HIV [20] Injecting drugs, smoking
crack cocaine
– 7 ↑
[25] Illicit drug use – 7 ↑
[24] Injection drug use – Unclear ↑
HCV [26] PWID Community based studies
and blood donors
Prevalence of HCV: ↑
PWID 44.71% (37.5–52.03) 46
Community 0.85% (0.00–3.98) 4
Blood donors 0.44% (0.40–0.49) 211
[27] PWID General population Prevalence of HCV: ↑
PWID 52.2% (46.9–57.5) 56
General pop. 0.3% (0.2–0.4) 122
[28] PWID General population Prevalence of HCV: ↑
PWID 53.6% (36.2–70.6) 15
General pop. 6.2% (5.7–6.7) 148
[29] PWID – 7 ↑
Obesity as a risk factor




[31] Obesity (BMI: 30–39.9 kg/
m2)
Normal weight CAP: RR 1.03 (CI 0.8–1.3) 10 ↑
Influenza related: RR 1.31 (1.05–1.63) 10
Nosocomial: RR 1.26 (0.80–1.98) 5
[32] Overweight and obesity Normal weight RR 1.33 (95% CI 1.04–1.71) 13 ↑
Smoking as a risk factor
HIV [20] Current smoking – 1 ↑
Pneumonia
[33] a) Current smoking Never smokers a) OR 2.17 (1.70–2.76) 13 ↑
b) Ever smoked b) OR 2.31 (1.99–2.69) 13
IBD (IPD) [23] Current or former smoking – 6 ↑
Second-hand smoke as a risk factor
TB [34] Exposure to ETS No exposure to ETS TB infection (children): OR 1.9 (0.9–2.9) 3 ↑
TB disease (children): OR 2.8 (0.9–4.8) 5
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on the number of reviews included for each risk factor
was not reported, the corresponding author of the paper
was contacted for additional information.
Due to the variety of different communicable diseases,
risk factor definitions, outcome measures, and methods
of reporting in the included studies, as well as the chal-
lenges of conducting meta-analysis for observational
studies [71], findings were not combined statistically
through meta-analysis. Instead, a narrative synthesis of
the findings was constructed [72], and effect size ranges
reported for each behavioural risk factor. Key informa-
tion that would have enabled calculation of a common
effect size was often not available. To calculate these ef-
fect size ranges, it was assumed that ORs, RRs and rate
ratios were approximately equivalent, a method sug-
gested for umbrella reviews in these circumstances [73].
In addition, where studies reported reduced risk of a
communicable disease with a health behaviour (e.g.
physical activity, no alcohol drinking), an inverse OR
(1/OR) for the corresponding risk behaviour was re-
ported. Findings were structured according to the iden-
tified behavioural risk factors and their association with
a) contraction of the identified communicable diseases,
and b) experiencing more severe outcomes from these
communicable diseases. Some study conclusions were
amended for readability, to aid understanding. Further,
where study conclusions were not relevant to the
current research question, information was extracted
from results sections and amended for readability (see
Supplementary file 2).
Methodological quality of studies
The methodological quality of included studies was
assessed using the Overview Quality Assessment
Questionnaire (OQAQ); a frequently used, validated tool
for assessing the methodological quality of systematic re-
views [74]. Methodological quality assessment was car-
ried out by three researchers (NJ, SH, SW), with any
discrepancies resolved through discussion. Assessment
ratings are available in Supplementary file 2.
Results
The database search yielded 1806 citations, of which 53
were included (Fig. 1). Research relating to the following
communicable diseases (including infection and patho-
gens) was identified: TB, HIV, hepatitis C virus (HCV),
hepatitis B virus (HBV), invasive bacterial disease (IBD),
pneumonia, influenza, and COVID-19. No studies relat-
ing to SARS, MERS or meningitis were identified.
Thirty-six of the identified systematic reviews also con-
ducted meta-analyses. Reviews used a range of defini-
tions of behavioural risk factors (e.g. current or former
smoker, any alcohol use or heavy alcohol use). All defini-
tions were included in the synthesis, and are presented
for clarity in each section of the results and in the results
tables (Tables 1 and 2). Eighteen reviews examined the
Table 1 Results and main conclusions relating to identified risk factors from included studies: risk of contraction (Continued)
Disease
contracted
Ref Definition of risk factor Meta-analysis findings No. of
studiesa
Conclusionb
Comparison group Effect size (95% CI) Effect
direction
[35] Exposure to SHS No exposure to SHS TB infection (children): RR 1.19 (0.90–1.57) 6 ↑—
TB disease: RR 1.59 (1.11–2.27) 6
[36] Exposure to SHS No exposure to SHS TB infection: RR 1.67 (1.12–2.48) and adjusting
for age/SES, RR 1.11 (0.90–1.57)
6 –
TB disease: RR 1.96 (1.37–2.80) and adjusting
for age/SES, RR 2.13 (1.18–3.83)
12
Pneumonia
[33] Exposure to ECS No exposure to ECS Aged 65+: OR 1.64 (1.17–2.30) 2 ↑—
All ages: OR 1.13 (0.94–1.36) 5
IBD [37] Exposure to SHS No exposure to SHS IMD: OR 2.02 (1.52–2.69) 16 ↑—
IHD: OR 1.22 (0.93–1.62) and 12
IHD (pre-schoolers) OR 1.46 (1.19–1.81) 9
IPD: OR 1.21 (0.69–2.14) 4
Physical inactivity as a risk factor
Influenza
Pneumonia
[38] Lack of prolonged,
moderate aerobic exercise
– 7 ↑
a Number of studies for either the meta-analysis or (for narrative reviews) the risk factor. b Conclusion statements are included in Supplementary file 2. Effect
direction is based on conclusions: ↑ = increased risk; ↓ = decreased risk; — = no association. OR Odds ratio, RR Relative risk, TB Tuberculosis, HIV Human
immunodeficiency virus, HCV Hepatitis C virus, IBD Invasive bacterial disease, IPD Invasive pneumococcal disease, IMD Invasive meningococcal disease, IHD
Invasive Hib disease, CAP Community acquired pneumonia, AUD Alcohol use disorder, BMI Body mass index, SHS Second-hand smoke, ETS Environmental tobacco
smoke, ECS Environmental cigarette smoke, PWID People who inject drugs
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Table 2 Results and main conclusions relating to identified risk factors from included studies: risk of more severe outcomes





Meta-analysis (MA) findings No. of
studiesa
Conclusionb
Comparison group Effect size (95% CI) Effect
direction
Alcohol as a risk factor
TB [39] Death Alcoholism – Unclear ↑
[40] Treatment default, failure
or death
Alcohol misuse No alcohol misuse RR 1.45 (1.21–1.74) 15 ↑
[41] MDR TB Alcohol use – 8 ↑
[19] Poor outcomes Alcohol use – Unclear –
[42] Relapse after treatment Alcoholism – 1 ↑
[43] Unsuccessful treatment Alcohol use No alcohol use OR 2.0 (1.67–2.50) 9 ↑
[44] Death, treatment failure,
lost to follow up






HIV [45] Poor treatment outcomes Alcohol use disorders – 10 ↑
[46] Viral non-suppression Alcohol use No alcohol use OR 2.47 (1.58–3.87) 6 ↑
[47] HIV progression, survival Alcohol use – 17 ~
HCV [48] No spontaneous clearance Current/history of
excess use
No history of excess use OR 1.49 (1.05–2.13) 5 ↑
[49] No achievement of SVR Alcohol use – 10 ↑
Illicit drug use a risk factor
TB [39] Death Injection drug use – Unclear ↑
[41] MDR-TB Drug abuse – 7 ↑
[19] Poor outcomes Drug abuse – Unclear –
HIV [50] AIDS-related mortality Regular/problem
cocaine use
General pop. SMR 23.12 (11.30–
47.31)
6 ↑
HCV [48] No spontaneous clearance History of injection drug
use
Non-injecting drug use OR 1.69 (1.08–2.70) 7 ↑
[51] Reinfection with HCV Recent drug use Receiving OAT with no
recent drug use
OAT: aRR 3.50 (1.62–
7.53)
21 ↑
No OAT: aRR 3.96
(1.82–8.59)
15
[52] No achievement of SVR Recent People who
inject drugs (PWID)
Non recent PWID RR 1.01 (0.95–1.08) 10 –













Obesity as a risk factor
Influenza [54] ICU admission or death a) Obesity, BMI ≥30 kg/
m2
a) Not obese a) OR 2.14 (0.92–
4.99)
5 ↑
b) Morbid obesity ≥40
kg/m2
b) Not morbidly obese b) OR 2.01 (1.29–
3.14)
5
[30] Higher level of healthcare Obesity and morbid
obesity
– 7 ↑
[55] Death Obesity BMI > 30 kg/m2 Not obese OR 2.74 (1.56–4.80) 33 ↑
[56] a) Hospital admission Obesity BMI > 30 kg/m2 Not obese a) RR 1.82 (1.48–
2.24)
15 ↑
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Table 2 Results and main conclusions relating to identified risk factors from included studies: risk of more severe outcomes
(Continued)





Meta-analysis (MA) findings No. of
studiesa
Conclusionb
Comparison group Effect size (95% CI) Effect
direction






COVID-19 [57] Poor outcomes Obesity 9 ↑—
[58] ICU admission, IMV or
death
Obesity Non-obese RR 1.40 (0.91–2.17) 3 ↑
[59] Worse outcomes Obesity or overweight 20 ↑
[60] a) ICU admission Obesity (BMI Asians >
25 kg
Non-obese a) OR 1.21 (1.00–
1.46)
6 ↑
b) IMV /m2, Caucasians > 30 kg/
m2)




[32] Mortality Overweight and obesity Normal weight RR 0.83 (0.77–0.91) 10 ↓
Smoking as a risk factor
TB [39] Death Smoking Unclear –
[41] DR TB Smoking 13 ↑
[19] Poor outcomes Smoking Unclear ↑
[43] Unsuccessful treatment Smoking 16 ↑
[40] Treatment default, failure
or death
Smoking Non-smokers RR 0.94 (0.75–1.19) 11 –
[61] a) Unfavourable outcomes Current cigarette
smoking





b) OR 1.55 (1.04–
2.07)
5
[42] Relapse after treatment Smoking 2 ↑
[62] DR TB Current/past smoking Non-smokers OR 1.57 (1.33–1.86) 33 ↑
Influenza [56] a) Hospital admission Tobacco smoking Non-tobacco smokers a) RR 1.24 (1.07–
1.43)
10 ↑
b) ICU admission or death b) RR 1.46 (1.25–
1.69)
30
COVID-19 [63] Adverse outcomes Current smoking Non-current smokers OR 1.53 (1.06–2.20) 18 ↑
[64] ARDS, ICU admission or
death
Smoking Non-smokers OR 1.54 (1.07–2.22) 5 ↑
[65] ICU, severe oxygenation,
IMV, death
Current smoking Past/never smokers RR 1.45 (1.03–2.04) 2 ↑
[66] ICU admission or death a) History of smoking Non-smokers a) OR 2.17 (1.37–
3.46)
16 ↑
b) Current smoking b) OR 1.51 (1.12–
2.05)
10






[68] Worsening of symptoms,
ICU, death
a) Current smoking Non-smokers a) OR 1.98 (1.16–
3.39)
13 ↑
b) Former smoking b) OR 3.46 (2.46–
4.85)
4
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association between behavioural risk factors and the
contraction of a communicable disease only, 32 reviews
examined the association between behavioural risk fac-
tors and the outcomes from communicable diseases
only, and three reviews examined associations with both
contraction of and outcomes from communicable dis-
eases. Characteristics of all included reviews and their
conclusions can be found in Supplementary file 2. No
systematic review had extensive or major flaws, with
most reviews having only minimal or minor flaws
Table 2 Results and main conclusions relating to identified risk factors from included studies: risk of more severe outcomes
(Continued)





Meta-analysis (MA) findings No. of
studiesa
Conclusionb
Comparison group Effect size (95% CI) Effect
direction
Second-hand smoke as a risk factor
Pneumonia
[69] Death from ALRIs (incl.
pneumonia)
SHS exposure No SHS exposure (Children) OR 1.52
(1.20–1.93)
8 ↑
Poor diet as a risk factor
HIV [70] HIV progression, mortality Vit.D deficiency/
insufficiency
10 ↑
HCV [49] No achievement of SVR Poor quality diet 2 –
a Number of studies for either the meta-analysis or (for narrative reviews) the risk factor. b Conclusion statements are included in Supplementary file 2. Effect
direction is based on conclusions: ↑ = increased risk; ↓ = decreased risk; — = no association; ~ = variable results. OR Odds ratio, RR Relative risk, aRR Adjusted rate
ratio, SMR Standardised mortality ratio, TB Tuberculosis, DR-TB Drug-resistant tuberculosis, MDR-TB Multi-drug resistant tuberculosis, DS-TB Drug-susceptible
tuberculosis, HIV Human immunodeficiency virus, AIDS Acquired immunodeficiency syndrome, HCV Hepatitis C virus, HBV Hepatitis B virus, HDV Hepatitis D virus,
ARDS Acute respiratory distress syndrome, ARLI Acute lower respiratory infection, PWID People who inject drugs, IVDU Intravenous drug user, SHS Second-hand

























Excluded, N = 1148
Duplicated (N = 10)
Non-English (N = 1)
Not a systematic review (N = 87)
Association between risk factor and 
communicable disease contraction/outcomes 
not examined (N = 990)
Selected sub-population (N = 60)
Excluded, N = 76
Full text unavailable (N = 1)
Redacted (N = 1)
Duplicated (N = 1)
Not a systematic review (N = 10)
Association between risk factor and 
communicable disease contraction/outcomes 
not examined (N = 34)
Selected sub-population (N = 25)
Not relevant to HICs (N = 4)
Excluded, N = 529
Duplicate (N = 529)
Fig. 1 PRISMA flow diagram of study identification, inclusion and exclusion
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(Supplementary file 2). Consequently, no reviews were
excluded based on methodological quality. A break-
down of reviews by disease and risk factors is pro-
vided in Supplementary file 3.
Behavioural risk factors for communicable diseases
Overall, 50 out of 53 reviews (94%) concluded that at
least one of the behavioural risk factors studied in-
creased the risk of contracting or having more severe
outcomes of a communicable disease. Across all reviews,
effect sizes, where calculated, ranged from 0.83 to 8.22
(Figs. 2 and 3; Tables 1 and 2). Nineteen out of 21
reviews (90%) concluded that at least one of the
behavioural risk factors studied increased the risk of
contracting a communicable disease (Table 1). Across all
contraction reviews, effect sizes, where calculated,
ranged from 1.03 to 8.22 (Fig. 2). Thirty-two out of 35
reviews (91%) concluded that at least one of the behav-
ioural risk factors studied increased the likelihood of
having more severe outcomes from a communicable dis-
ease (Table 2). Across all outcome reviews, effect sizes,
where calculated, ranged from 0.83 to 3.96 (Fig. 3).
Alcohol as a risk factor
Seventeen reviews included alcohol as a risk factor for a
communicable disease, with a range of definitions used:
any alcohol consumption [19, 23, 41, 43, 44, 46, 47, 49];
any alcohol use or higher amounts [18, 21]; binge drink-
ing or alcohol misuse [20]; alcohol misuse [40]; alcohol
use disorder (AUD) [22, 45]; alcoholism [39, 42]; or
current/history of excess use [48]. The majority of re-
views reported an increased risk of contraction (5/6 re-
views; Table 1) and more severe outcomes (10/12
reviews; Table 2). Across all alcohol reviews, effect sizes,
where calculated, ranged from 1.83–8.22 for contraction
(Fig. 2) and 1.45–2.47 for severe outcomes (Fig. 3). Alco-
hol use (any use, higher amounts, binge drinking or
AUD) was reported to increase the risk of contracting
TB [18], HIV [20], pneumonia [21, 22] and invasive
pneumococcal diseases (IPD) [23]. One review did not
draw a conclusion, but reported mixed findings for the
association between alcohol consumption and contrac-
tion of TB [19]. Alcohol use (any use, misuse, current/
history of excess use, alcoholism or AUD) was reported
to increase the risk of having more severe outcomes
from TB [39–44], HIV [45, 46], and HCV [48, 49]. One
review reported mixed findings and made no clear con-
clusion about the association of alcohol consumption
and TB outcomes [19], and one review reported variable
results among studies examining the association between
alcohol consumption and the progression of HIV [47].
Illicit drug use as a risk factor
Fifteen reviews examined the association between illicit
drug use and communicable disease contraction or out-
comes, with a wide range of definitions used: drug abuse
[19, 41]; illicit drug use [25]; regular/problem cocaine
use [50]; recent drug use [51]; and injection drug use
[20, 24, 26–29, 39, 48, 52, 53]. The majority of reviews
reported an increased risk of contraction (8/9 reviews;
Table 1) and more severe outcomes (6/8 reviews; Table
2). Across all drug use reviews, effect sizes, where calcu-
lated (for more severe outcomes only), ranged from
1.01–3.96 (Fig. 3). Both injection drug use and illicit
drug use were reported to increase the risk of contract-
ing TB [24] and HIV [20, 24, 25], whilst the prevalence
of HCV was found to be higher among people who in-
ject drugs (PWID) compared to general population or
community groups [26–29]. One review did not draw a
conclusion but reported mixed findings for the
Fig. 2 Forest plot of meta-analysis effect sizes: contraction of a communicable disease. Effect sizes refer to odds ratios and relative risks, see Table
1 for more information. CAP = community acquired pneumonia; TB = tuberculosis; IBD = invasive bacterial disease
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association between drug abuse and TB contraction [19].
Both injecting drug use and drug use/abuse were re-
ported to increase the risk of having more severe out-
comes from TB [39, 41], HIV [50] and HCV [48, 51].
Furthermore, among those with HBV, the prevalence of
hepatitis D (HDV; co-infection with HDV is considered
a more severe form of viral hepatitis) was substantially
higher for PWID compared to a mixed population
with no risk factors [53]. One review did not draw a
conclusion but reported mixed findings for the associ-
ation between drug abuse and TB outcomes [19], and
one review concluded that treatment outcomes for
HCV were similar between people who currently were
and were not injecting drugs [52].
Physical inactivity as a risk factor
One systematic review was identified examining the as-
sociation between physical activity and communicable
disease contraction or outcomes. This study reported an
association between increased prolonged, moderate aer-
obic exercise and reduced influenza-related mortality,
and improved immunocompetence [38].
Obesity as a risk factor
Ten reviews focused on the relationship between obesity
[30, 31, 54–58, 60], or overweight and obesity [32, 59],
and communicable disease risk. The majority of reviews
reported an increased risk of contraction (3/3 reviews;
Table 1) and more severe outcomes (8/9 reviews; Table
2). Across all obesity reviews, effect sizes, where calcu-
lated, ranged from 1.03–1.33 for contraction (Fig. 2) and
0.83–2.74 for severe outcomes (Fig. 3). Obesity was re-
ported to increase the risk of contracting influenza [30]
and pneumonia [31, 32]. Obesity was reported to
increase the risk of having more severe outcomes from
influenza [30, 54–56] and COVID-19 [58–60]. One re-
view concluded that most studies showed some degree
of association between higher body mass index (BMI)
and a worse clinical presentation of COVID-19 and the
need for hospitalisation. This review suggested that
obesity seemed to predict poor clinical evolution in pa-
tients with COVID-19, but that studies in the review
had limited methodological quality [57]. However, one
review, which concluded that obesity increased the risk
of contracting pneumonia, also found that obese individ-
uals had a lower mortality risk from pneumonia [32].
Smoking as a risk factor
Eighteen reviews examined the association between
smoking (current, past or both) and communicable dis-
ease contraction or outcomes. The majority of reviews
reported some evidence of an increased risk of contrac-
tion (3/3 reviews; Table 1) and more severe outcomes
(13/15 reviews; Table 2). Across all smoking reviews, ef-
fect sizes, where calculated, ranged from 2.17–2.31 for
contraction (Fig. 2) and 0.94–3.46 for severe outcomes
(Fig. 3). Smoking was reported to increase the risk of
contracting HIV [20], pneumonia [33] and invasive
pneumococcal disease (IPD) [23]. Further, smoking was
reported to increase the risk of having more severe out-
comes from TB [19, 41–43, 61, 62], influenza [56], and
COVID-19 [63–66, 68]. Two reviews reported no associ-
ations between smoking and more severe outcomes from
communicable diseases, including death from TB [39]
and TB treatment outcomes [40]. One review reported
that active smoking may increase the risk of severe
COVID-19, but found the result was heavily influenced
by one study [67].
Fig. 3 Forest plot of meta-analysis effect sizes: more severe communicable disease outcomes. Effect sizes refer to odds ratios, relative risks and
rate ratios, see Table 2 for more information. MDR =multi-drug resistant; TB = tuberculosis; DS = drug-susceptible; HIV = human immunodeficiency
virus; HCV = hepatitis C virus; ICU = intensive care unit; IMV = invasive mechanical ventilation; OAT = opioid agonist therapy
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Second-hand smoke as a risk factor
Six reviews focused on second-hand smoke as a risk fac-
tor for a communicable disease. The majority of reviews
reported some evidence of an increased risk of contrac-
tion (4/5 reviews; Table 1) and more severe outcomes
(1/1 review; Table 2). Across all second-hand smoking
reviews, effect sizes, where calculated, ranged from 1.11
to 2.80 for contraction (Fig. 2), and the one effect size
calculated for severe outcomes was 1.52 (Fig. 3). One re-
view suggested that second-hand smoke exposure in-
creased the risk of TB infection and disease [34]. The
remaining four reviews reported at least some evidence
of second-hand smoke exposure increasing the risk of
contracting a communicable disease, including TB [35,
36], pneumonia (among those aged 65+ only) [33], and
IBD (invasive meningococcal disease [IMD] only) [37].
Second-hand smoke exposure was reported to increase
the risk of severe outcomes from acute lower respiratory
infections (ALRIs), including pneumonia [69].
Poor diet as a risk factor
Only two reviews were identified that examined the as-
sociation between poor diet and communicable disease
outcomes, and no reviews examining the association be-
tween poor diet and communicable disease contraction
were identified. One review found that vitamin D status
may influence the course of HIV disease [70]. The sec-
ond review reported that a high intake of polyunsatur-
ated fatty acids was associated with non-response to
HCV antiviral therapy [49].
Discussion
The key finding of this systematic review is that behav-
ioural risk factors play a significant role in the risk of
contracting, and having more severe outcomes from,
common communicable diseases. To the authors’ know-
ledge, this is the first time that a review has brought to-
gether studies exploring the impact of behavioural risk
factors on a range of communicable diseases. Whilst the
focus on selected communicable diseases and use of sys-
tematic reviews has led to inevitable gaps, the findings
nevertheless provide strong evidence that both NCDs
and communicable diseases share a common set of be-
havioural risk factors. This work indicates that the pre-
vention of communicable disease is likely to be most
successful if it involves the prevention of behavioural
risk factors. These findings are timely, in light of the
COVID-19 pandemic, and highlight potential additional
benefits of addressing behavioural risk factors ahead of
any future epidemics or pandemics. While the specific
diseases that may be involved can only be speculated,
they are likely to share at least some characteristics with
diseases in this review.
Although this review has not examined the mecha-
nisms connecting behavioural risk factors and commu-
nicable diseases, there are likely to be multiple
mechanisms. Behavioural factors, such as alcohol use,
smoking, obesity, and illicit drug use, are well docu-
mented to impair the immune system. For instance,
smoking is known to influence both innate and adaptive
immunity [75]. Impairments to the immune system can
make individuals more susceptible to communicable dis-
eases and less able to control or recover from infection,
leading to worse outcomes [76–81]. Use of alcohol/drugs
may also reduce the efficacy of treatment for communic-
able diseases [82]. The presence of comorbidities, such
as diabetes and cardiovascular disease, in individuals
with behavioural risk factors has also been implicated in
the increased risk of communicable diseases [83, 84].
However, behavioural risk factors, such as obesity, are
also reported to independently influence communicable
diseases, after adjusting for comorbidities [55]. Behav-
ioural mechanisms may also be important, particularly
for alcohol and drug use, which may reduce risk percep-
tion [78], interfere with the uptake of services, or lead to
poorer treatment adherence [85]. Additionally, behav-
ioural risk factors may be likely to appear in combin-
ation, for example combined alcohol use and smoking
[86], to further increase influences on communicable
diseases. Furthermore, behaviours associated with drug
use, such as injecting drugs, have a high efficiency of
transmission of communicable diseases and reinfection
with communicable diseases [87]. Having a communic-
able disease could also lead to the presence of behav-
ioural risk factors (e.g. alcohol may be used as a way of
coping with the emotional distress of diseases such as
HIV and HCV [88]). Finally, there may be social mecha-
nisms, such as the social marginalisation of heavy
drinkers that affects health service use or treatment [89],
or social issues such as homelessness, incarceration and
poverty, which may increase the risk of both behavioural
risk factors and communicable diseases [90, 91]. It is
likely that there are multiple ways in which these differ-
ent physiological, behavioural and social factors come
together to affect the likelihood of transmission and se-
verity of communicable disease, which require further
investigation.
With behavioural risk factors influencing the contrac-
tion and severity of communicable diseases, their pre-
vention is likely to play a role in addressing future
communicable disease burden, potentially through im-
provements in the immune system, bodily functioning
and risk behaviours. As the recent COVID-19 pandemic
has highlighted, their prevention is also likely to impact
on communicable disease burden through the potential
reduction of NCDs commonly associated with behav-
ioural risk factors, which can also alter immune system
Wood et al. BMC Public Health         (2021) 21:2110 Page 11 of 16
function [92] and increase the risk of communicable dis-
ease complications and death [10, 93]. The review find-
ings are important in understanding communicable
disease risk, and timely, in light of COVID-19. They sug-
gest that improvements in the prevention of behavioural
risk factors may serve to reduce the negative impacts of
future epidemics or pandemics, building resilience and
helping to address the pressing need for greater invest-
ment in pandemic preparedness [94]. Indeed, COVID-19
should not only be a reminder that good communicable
disease control is necessary, but that the more successful
we are in addressing behavioural risk factors, the better
we will also be at reducing the burden of communicable
disease, including future epidemics or pandemics. The
finding that both communicable diseases and NCDs
share a common set of behavioural risk factors also
lends support for a more holistic understanding of these
two disease categories. For instance, research suggests
that NCDs and communicable diseases can interact;
whilst NCDs can increase the risk and severity of com-
municable diseases (e.g. individuals with diabetes, hyper-
tension and respiratory illnesses are more likely to
affected by COVID-19 [95]), at least some diseases pre-
viously considered NCDs are now known to have an in-
fectious origin (e.g. HBV is a cause of heptatocellular
carcinoma [96]).
Although the focus of this review is on HICs, findings
will be of importance to LMICs, which often experience
a much higher burden of communicable disease [9] and
where, for many countries, the prevalence of behavioural
risk factors is increasing [7, 8]. Due to ageing popula-
tions, the negative impacts of globalisation, and ill-
equipped health systems, these countries are also facing
a rapidly growing burden of NCDs [97–99], which may
reduce resistance to infection, increase communicable
disease complications, or interfere with its treatment
[100, 101]. In the current global society, any negative ef-
fects of rising behavioural risk factors and related NCDs
on communicable disease transmission have the poten-
tial to affect not only LMICs, but health and well-being
globally.
Across both HICs and LMICs, behavioural risk factors
and related NCDs are known to cluster in disadvantaged
populations [97, 102–104], with poverty contributing to
behavioural risk factors and NCDs, and vice versa [97].
Disadvantaged communities are more likely, therefore,
to experience dual burdens of NCDs and communicable
disease, contributing to social and economic health in-
equalities. In the UK for instance, people living in the
most disadvantaged communities have been over twice
as likely to die from COVID-19 as those in the least
disadvantaged areas [105]. Preventing behavioural risk
factors, particularly among disadvantaged populations, is
likely to play an important role in reducing future global
and national health inequalities, as well as the unequal
burden of future pandemics.
There are some limitations to this work. The wide-
ranging nature of the research allowed for a broad view
of the links between behavioural risk factors and com-
municable diseases. However, this did not allow for the
exploration of causal pathways of specific associations.
Further research exploring these pathways would aid un-
derstanding and inform prevention. The use of system-
atic reviews to achieve a broader range of information
also meant that newer empirical research may have been
missed, only more widely researched topics for which
there is enough information to conduct a systematic re-
view would have been included, and more in-depth in-
formation such as potential interactions between risk
factors could not be included. With no single definitions
of behavioural risk factors agreed across the literature, it
was not possible to standardise the definitions of risk
factors in this review, meaning that there was often
variation in the definitions included in each risk factor
category, hampering discussion of relationships. Low
socio-economic status (SES) and other factors associated
with low SES, such as poor housing, are likely to be an
important element in the link between behavioural risk
factors and communicable diseases, although little is
currently known about the influence of low SES and as-
sociated factors. It was not possible to explore the role
of low SES within the review since many of the reviews
included did not explore low SES in their analyses. Many
of the included studies are global syntheses, however,
the relationships between behavioural risk factors and
communicable diseases may vary between countries.
Only papers written in English were included, meaning
that research in other languages may have been missed.
Finally, conclusions should be considered with publica-
tion bias in mind; papers are more likely to be published
if they reveal significant effects rather than null findings
[106], so those reporting that behavioural risk factors are
associated with communicable diseases are more likely
to be identified.
This work identified several gaps in the current system-
atic review literature relating to specific behavioural risk
factors and common communicable diseases, including
studies examining the association of physical inactivity
and poor dietary habits with communicable diseases,
which warrant urgent further exploration. For instance,
recently published literature has indeed highlighted the
important role of physical inactivity in severe COVID-19
risk [2, 107]. Due to the study being limited to systematic
reviews only, a comprehensive comparison of behavioural
risk factors across different disease types could not be pro-
vided; although future reviews could provide such com-
parisons. However, it was noted that reviews examining
the association of communicable diseases with alcohol
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and illicit drug use largely focused on TB, HIV and hepa-
titis, whereas reviews examining association with obesity
largely focused on pneumonia, influenza and COVID-19
(see Supplementary file 3). Further research understanding
the more intricate ways in which individual behavioural
risk factors are linked to specific types of disease, and the
mechanisms by which they are linked, would provide a
valuable framework for understanding how current and
future communicable diseases may affect different popula-
tion groups. Finally, findings highlight an opportunity for
future research to examine the efficacy of behavioural risk
factor prevention efforts in reducing communicable dis-
ease burden.
Conclusions
Behavioural risk factors play a significant role in the risk
of contracting, and having more severe outcomes from,
common communicable diseases. These risk factors are
largely modifiable or preventable. Prevention of commu-
nicable diseases is likely to be most successful if it in-
volves the prevention of behavioural risk factors that are
commonly associated with NCDs, particularly among
disadvantaged populations. These findings are important
for understanding risks associated with communicable
disease, and timely, given the current COVID-19 pan-
demic and need for improvements in future pandemic
preparedness. Addressing behavioural risk factors should
be an important part of work to build resilience against
any emerging and future epidemics and pandemics. Fur-
thermore, the pandemic can offer a timely, teachable
moment for the public on how improvements to general
health, through addressing risk behaviours commonly
associated with NCDs, may help protect them from in-
fections like COVID-19 in the future.
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